

Product News

Cicalfate Hand

Pierre Fabre Dermo-Cosmétique USA adds a restorative hand cream to the Cicalfate product line available exclusively through physicians. Cicalfate Hand is a rich cream that is formulated to nourish, restore, and protect chapped and irritated hands from various types of aggression. The active ingredients work to heal skin and prevent bacterial proliferation. Avène Thermal Spring Water acts as an anti-inflammatory agent to soothe and soften the skin. Cicalfate Hand is transparent when applied; it is nonsticky and absorbs rapidly, creating a protective veil around hands to prevent against dehydration and sealing in the power of skin-restoring agents. It may be applied twice daily, concentrating on the most cracked and irritated areas. For more information, visit www.avenusa.com.

D-E-J Eye Cream

Revision Skincare launches the D-E-J Eye Cream to help tighten and brighten the entire eye area. This intensive antiaging eye cream specifically targets the dermoepidermal junction to improve the look of fine lines, firmness, overall photodamage, upper eyelid appearance, and elasticity. Advanced extracts, peptides, and a blend of antioxidants work together to provide a younger-looking appearance with twice-daily application. For more information, visit www.revisionskincare.com.

Noxafil

Merck & Co, Inc, announces US Food and Drug Administration approval of Noxafil (posaconazole) injection (18 mg/mL), an antifungal agent indicated for prophylaxis of invasive *Aspergillus* and *Candida* infections in patients who are at high risk for developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy. Noxafil also is available as delayed-release tablets (100 mg) and oral suspension (40 mg/mL). Noxafil injection is indicated in patients 18 years and older; the delayed-release tablets and oral suspension are indicated in patients 13 years and older. The availability of Noxafil for intravenous administration is important for patients who may benefit from or require intravenous therapy instead of oral therapy. Patients have the possibility of starting on Noxafil injection and transitioning to the oral formulation. Noxafil injection is administered with a loading dose of 300 mg twice daily on the first day of therapy, then 300 mg once daily thereafter. Duration of therapy is based on recovery from neutropenia or immunosuppression. For more information, visit www.merck.com.

If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.